Last reviewed · How we verify
BR5402C
BR5402C is a small molecule that targets the HIF-1α pathway.
BR5402C is a small molecule that targets the HIF-1α pathway. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | BR5402C |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | HIF-1α inhibitor |
| Target | HIF-1α |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BR5402C works by inhibiting the activity of HIF-1α, a protein that plays a key role in the body's response to low oxygen levels. This inhibition leads to a decrease in the production of angiogenic factors, which are involved in the formation of new blood vessels. By targeting the HIF-1α pathway, BR5402C aims to reduce tumor growth and metastasis.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR5402C CI brief — competitive landscape report
- BR5402C updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI